(±) -Lisofylline

• Description :

  (±) -Lisofylline ((±) -Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1].

• Product Name Alternative :

  (±) -Lisophylline

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Interleukin Related

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/racemic-lisofylline.html

• Concentration :

  10mM

• Purity :

  99.93

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N1CCCCC(O)C)N(C)C2=C(N(C)C=N2)C1=O

• Molecular Formula :

  C13H20N4O3

• Molecular Weight :

  280.33

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations :

  [1]Yang Z, et al. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69 (1) :1-5.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [6493-06-7]